| Literature DB >> 29157924 |
Jonathan A Cook1, Graeme S MacLennan2, Tom Palmer3, Noemi Lois4, Richard Emsley5.
Abstract
OBJECTIVES: Randomization can be used as an instrumental variable (IV) to account for unmeasured confounding when seeking to assess the impact of noncompliance with treatment allocation in a randomized trial. We present and compare different methods to calculate the treatment effect on a binary outcome as a rate ratio in a randomized surgical trial. STUDY DESIGN ANDEntities:
Keywords: Binary; Causal modeling; Instrumental variable; Noncompliance; RCT; Risk ratio
Mesh:
Year: 2017 PMID: 29157924 PMCID: PMC5862096 DOI: 10.1016/j.jclinepi.2017.11.011
Source DB: PubMed Journal: J Clin Epidemiol ISSN: 0895-4356 Impact factor: 6.437
Number of participants who received peeling by randomized group (N [%])
| Time from baseline | Peeling group ( | No peeling group ( |
|---|---|---|
| 1 month | 64 (90) | 4 (6) |
| 3 months | 64 (90) | 27 (40) |
| 6 months | 64 (90) | 29 (43) |
Fig. 1Graphical representation of a trial with noncompliance, with randomization as an instrumental variable for the treatment received.
Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study trial—baseline variables by randomized group and compliance groups at 6 months
| Key baseline measures, mean (SD) | Randomized group | Compliance (6 months) | Compliers (6 months) by randomized groups | |||
|---|---|---|---|---|---|---|
| Peel (n = 71) | No Peel (n = 67) | Complier (n = 102) | Noncomplier (n = 36) | Peel (n = 64) | No peel (n = 38) | |
| Age | 70 (6) | 71 (6) | 71 (6) | 71 (6) | 70 (6) | 71 (6) |
| Stage of hole (stage 3), | 42 (59) | 41 (61) | 58 (57) | 25 (67) | 38 (59) | 20 (54) |
| EDTRS visual acuity study eye | 48 (14) | 50 (11) | 48 (10) | 48 (10) | 48 (14) | 52 (11) |
| EDTRS visual acuity fellow eye | 76 (14) | 76 (17) | 78 (11) | 78 (11) | 76 (14) | 75 (20) |
| EuroQol 5 Dimensions 3 Levels | 0.80 (0.21) | 0.88 (0.13) | 0.84 (0.14) | 0.84 (0.14) | 0.80 (0.21) | 0.90 (0.13) |
| Visual Function Questionnaire-25 | 80 (16) | 80 (18) | 79 (21) | 79 (21) | 79 (16) | 82 (13) |
Macular hole status by time point and randomized group (N [%] closed)
| Time point | Randomized groups | |
|---|---|---|
| Peeling group ( | No peeling group ( | |
| 1 month | 56 (84) | 31 (48) |
| 3 months | 61 (92) | 52 (83) |
| 6 months | 61 (94) | 56 (89) |
Risk ratio results (95% CI/causal bounds)
| Outcome | Compliance | Method | Point estimate (lower–upper) | |
|---|---|---|---|---|
| 1 month | ITT | 0.32 (0.18–0.58) | 0.001 | |
| C1 | PP | 0.26 (0.14–0.51) | <0.001 | |
| TR | 0.25 (0.13–0.49) | <0.001 | ||
| 2SRI | 0.26 (0.13–0.53) | <0.001 | ||
| Causal bounds | NA (0.24–0.38) | |||
| 3 month | ITT | 0.43 (0.16–1.18) | 0.103 | |
| C1 | PP | 0.35 (0.12–1.05) | 0.061 | |
| TR | 0.33 (0.11–0.97) | 0.044 | ||
| 2SRI | 0.37 (0.11–1.26) | 0.112 | ||
| Causal bounds | NA (0.27–0.69) | |||
| C2 | PP | 0.35 (0.11–1.12) | 0.078 | |
| TR | 0.48 (0.19–1.20) | 0.117 | ||
| 2SRI | 0.20 (0.02–1.60) | 0.129 | ||
| Causal bounds | NA (0.13–1.09) | |||
| 6 month | ITT | 0.55 (0.17–1.81) | 0.328 | |
| C1 | PP | 0.55 (0.17–1.80) | 0.326 | |
| TR | 0.55 (0.17–1.81) | 0.328 | ||
| 2SRI | 0.51 (0.13–1.99) | 0.331 | ||
| Causal bounds | NA (0.39–0.97) | |||
| C3 | PP | 0.45 (0.13–1.68) | 0.214 | |
| TR | 0.51 (0.16–1.66) | 0.238 | ||
| 2SRI | 0.31 (0.03–3.84) | 0.362 | ||
| Causal bounds | NA (0.12–1.36) |
Abbreviations: CI, confidence interval; ITT, intention to treat; PP, per protocol; TR, treatment received; 2SRI, two-stage residual inclusion approach.